Pharmaceutical Secondary Standard; Certified Reference Material

Norfloxacin, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazino-3-quinolinecarboxylic acid
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
EC Number:
MDL number:
PubChem Substance ID:

Quality Level


certified reference material
pharmaceutical secondary standard


current certificate can be downloaded


pkg of 1 g


HPLC: suitable
gas chromatography (GC): suitable

Featured Industry

Pharmaceutical (small molecule)



pharmacopeia traceability

traceable to BP 670
traceable to PhEur N1230000
traceable to USP 1471506

SMILES string




InChI key


Looking for similar products? Visit Product Comparison Guide

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Norfloxacin is a synthetic broad-spectrum antibacterial drug that is effective against various gram positive and gram negative bacteria. Its major application is in the treatment of urinary tract infections.


These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Norfloxacin may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and serum samples by high performance liquid chromatography (HPLC) and spectrophotometric methods.

Biochem/physiol Actions

Norfloxacin blocks DNA replication by interfering with an ATP-induced structural transition of DNA complexed with DNA gyrase (topoisomerase).
Mode of action: inhibits bacterial DNA replication
Antimicrobial spectrum: Gram-negative bacteria; less effective against Gram-positive bacteria

Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.


To see an example of a Certificate of Analysis for this material enter LRAC2802 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Kinetic spectrophotometric method for the determination of norfloxacin in pharmaceutical formulations.
Rahman N, et al.
European Journal of Pharmaceutics and Biopharmaceutics, 57(2), 359-367 (2004)
Quantitative determination of ciprofloxacin and norfloxacin in pharmaceutical preparations by high performance liquid chromatography.
Kassab N, et al.
Brazilian Journal of Pharmaceutical Sciences , 41(4), 507-513 (2005)
Flow injection spectrophotometric and chromatographic determination of ciprofloxacin and norfloxacin in pharmaceutical formulations.
Al-Momani I, et al.
Journal of Flow Injection Analysis, 25(2), 151-151 (2008)
Direct determination of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin, in pharmaceuticals and blood serum by HPLC.
Samanidou VF, et al.
Analytical and Bioanalytical Chemistry, 375(5), 623-629 (2003)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.